Showing results (91-100 of 166) with videos related to
Sort By:
Pageof 17
Blood|May 27, 2014
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational studyAnna Abrahamsson, Alexandra Albertsson-Lindblad, Peter N Brown, et al.Hemasphere|March 19, 2025
Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: Long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trialElin Forsgren, Rasmus R K Jørgensen, Hans Bentzen, et al.Leukemia & Lymphoma|June 1, 2023
Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 scoreRuth Salim, Simon Husby, Christian Winther Eskelund, et al.Leukemia & Lymphoma|November 28, 2017
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendationsMartin Dreyling, Igor Aurer, Sergio Cortelazzo, et al.Blood|June 30, 2016
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphomaAlexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2015
Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based StudyTarec Christoffer El-Galaly, Lasse Hjort Jakobsen, Martin Hutchings, et al.Blood Advances|June 30, 2023
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphomaAnna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, et al.Leukemia|July 26, 2023
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)Gabriel Scheubeck, Linmiao Jiang, Olivier Hermine, et al.British Journal of Haematology|April 2, 2014
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group studyLena Nordström, Sandra Sernbo, Patrik Eden, et al.British Journal of Haematology|August 5, 2020
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphomaJoana M Rodrigues, May Hassan, Catja Freiburghaus, et al.Pageof 17